Asteromop Hires Master’s- and Doctoral-Level Biologists to Validate AI Drug Hypotheses

[Financial News] Artificial intelligence (AI) company Asteromop is hiring master’s- and doctoral-level biologists for its in-house laboratory. The goal is to establish a research system in which researchers directly test AI-proposed hypotheses and use the results to inform subsequent hypotheses. The plan is to use experimental results to weed out low-probability hypotheses early and focus research resources on those requiring follow-up validation.
According to industry sources on the 13th, Asteromop is set to begin recruiting master’s- and doctoral-level researchers to work on drug development and research into treatments for intractable diseases. After recently opening its own wet lab and starting biological experiments, the company is hiring a lead to oversee research programs and researchers to handle experiments and analysis.
The positions are open to researchers with master’s or doctoral degrees in relevant fields, including life sciences, biotechnology, pharmacy and veterinary medicine, as well as experience conducting experiments with cells and animal models. Those hired will work with AI researchers to refine hypotheses and design and conduct experiments to test them. Key duties include efficacy assessments using cells and animal models, and sample analysis.
Asteromop’s “experimental closed loop” is an approach in which data from one experiment are used to refine the next hypothesis and test it again. The plan is to speed up research by having AI researchers and biologists repeat this process, centered on the company’s own laboratory. Depending on the research project, the company will also conduct joint research with contract research organizations (CROs) or other external institutions.
Asteromop plans to expand its laboratory staff and facilities in stages to match the scope of its research. Over the medium to long term, it is also considering building an autonomous laboratory to automate experiments and developing a therapeutic platform using its own AI models.
[email protected] Jang Min-kwon Reporter